Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/TGN1412> ?p ?o }
- TGN1412 abstract "TGN1412 (also known as CD28-SuperMAB and TAB08) was the working name of an immunomodulatory drug which was withdrawn from development after inducing severe inflammatory reactions in the first-in-man study in London in March 2006. The developing company, TeGenero Immuno Therapeutics, went bankrupt later that year.The commercial rights were then acquired by a Russian investor. The drug was renamed TAB08. The Russian biotechnology company TheraMAB conducted Phase I trials with a much lower dose (0.1%) of the antibody than was used in the London study, and they had planned to initiate Phase II trials in June 2015.Originally intended for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, TGN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family).In its first human clinical trials, it caused catastrophic systemic organ failure in the subjects, despite being administered at a supposed sub-clinical dose of 0.1 mg per kg; some 500 times lower than the dose found safe in animals. Six volunteers were hospitalized on 13 March 2006, at least four of these suffering from multiple organ dysfunction. Tentative opinions from an as-yet uncompleted inquiry suggest that the problems resulted from \"unforeseen biological action in humans\", rather than breach of trial protocols, and the case therefore has had important ramifications for future trials of potentially powerful clinical agents.Scientists in early 2007 put forth the theory that the drug acted in a different fashion in humans as compared with the laboratory animals in which the drug was first tried. The severe reactions in humans could have only occurred, they believe, in those with memory T lymphocytes. Animals raised in a sterile lab would presumably have no 'memory' of previous illnesses, thus would not exhibit the severe reactions that occurred in the human subjects. However this is a misunderstanding of the research: the research says that lab animals studied have fewer memory T cells than humans, and that stimulation through the CD28 receptor alone in memory T cells causes them to infiltrate organs and also activates them.The drug, which was designated as an orphan medical product by the European Medicines Agency in March 2005, was developed by TeGenero Immuno Therapeutics, tested by Parexel and manufactured by Boehringer-Ingelheim. TeGenero announced the first elucidation of the molecular structure of CD28 almost exactly one year prior to commencement of the TGN1412 phase I clinical trial.".
- TGN1412 atcPrefix "none".
- TGN1412 thumbnail T_cell_activation.svg?width=300.
- TGN1412 wikiPageExternalLink 270.
- TGN1412 wikiPageExternalLink dispatches.htm.
- TGN1412 wikiPageExternalLink 440855a.
- TGN1412 wikiPageExternalLink 4914546.stm.
- TGN1412 wikiPageExternalLink 5015224.stm.
- TGN1412 wikiPageExternalLink perspectives.php.
- TGN1412 wikiPageExternalLink textdoc?DB=EPODOC&IDX=DE10345008&F=8&QPN=DE10345008.
- TGN1412 wikiPageExternalLink textdoc?DB=EPODOC&IDX=US2006009382&F=0&QPN=EP1600164&RPN=EP1600164&DOC=cca34af198500dc47b33f0ab732cd3a34a.
- TGN1412 wikiPageExternalLink textdoc?DB=EPODOC&IDX=US2006009382&F=0&QPN=US2006009382&RPN=US2006009382&DOC=dcb66f26dd9a5108c88241fac27a21f198.
- TGN1412 wikiPageExternalLink 070122-10.html.
- TGN1412 wikiPageID "4402358".
- TGN1412 wikiPageLength "35363".
- TGN1412 wikiPageOutDegree "94".
- TGN1412 wikiPageRevisionID "705263358".
- TGN1412 wikiPageWikiLink Adverse_effect.
- TGN1412 wikiPageWikiLink Agonist.
- TGN1412 wikiPageWikiLink Angioedema.
- TGN1412 wikiPageWikiLink Antibody.
- TGN1412 wikiPageWikiLink B-cell_chronic_lymphocytic_leukemia.
- TGN1412 wikiPageWikiLink B_cell.
- TGN1412 wikiPageWikiLink Boehringer_Ingelheim.
- TGN1412 wikiPageWikiLink CD28.
- TGN1412 wikiPageWikiLink Category:2006_in_London.
- TGN1412 wikiPageWikiLink Category:All_articles_with_unsourced_statements.
- TGN1412 wikiPageWikiLink Category:Clinical_trial_disasters.
- TGN1412 wikiPageWikiLink Category:Monoclonal_antibodies.
- TGN1412 wikiPageWikiLink Category:Unnamed_monoclonal_antibodies.
- TGN1412 wikiPageWikiLink Chinese_hamster_ovary_cell.
- TGN1412 wikiPageWikiLink Chronic_fatigue_syndrome.
- TGN1412 wikiPageWikiLink Clinical_trial.
- TGN1412 wikiPageWikiLink Co-stimulation.
- TGN1412 wikiPageWikiLink Complementarity_determining_region.
- TGN1412 wikiPageWikiLink Corticosteroid.
- TGN1412 wikiPageWikiLink Crab-eating_macaque.
- TGN1412 wikiPageWikiLink Cytokine.
- TGN1412 wikiPageWikiLink Cytokine_release_syndrome.
- TGN1412 wikiPageWikiLink Cytokine_storm.
- TGN1412 wikiPageWikiLink Drug_development.
- TGN1412 wikiPageWikiLink Effector_cell.
- TGN1412 wikiPageWikiLink Eosinophil_granulocyte.
- TGN1412 wikiPageWikiLink EudraCT.
- TGN1412 wikiPageWikiLink EudraVigilance.
- TGN1412 wikiPageWikiLink European_Medicines_Agency.
- TGN1412 wikiPageWikiLink First-in-man_study.
- TGN1412 wikiPageWikiLink Good_clinical_practice.
- TGN1412 wikiPageWikiLink Gordon_Duff.
- TGN1412 wikiPageWikiLink HIV.
- TGN1412 wikiPageWikiLink Humanized_antibody.
- TGN1412 wikiPageWikiLink Immune_system.
- TGN1412 wikiPageWikiLink Immunosuppression.
- TGN1412 wikiPageWikiLink Immunotherapy.
- TGN1412 wikiPageWikiLink In_vitro.
- TGN1412 wikiPageWikiLink In_vivo.
- TGN1412 wikiPageWikiLink Intravenous_therapy.
- TGN1412 wikiPageWikiLink Joseph_Merrick.
- TGN1412 wikiPageWikiLink London.
- TGN1412 wikiPageWikiLink Lupus_erythematosus.
- TGN1412 wikiPageWikiLink Lymph_node.
- TGN1412 wikiPageWikiLink Lymphoma.
- TGN1412 wikiPageWikiLink Medicines_and_Healthcare_Products_Regulatory_Agency.
- TGN1412 wikiPageWikiLink Memory_T_cell.
- TGN1412 wikiPageWikiLink Mucous_membrane.
- TGN1412 wikiPageWikiLink Multiple_organ_dysfunction_syndrome.
- TGN1412 wikiPageWikiLink Multiple_sclerosis.
- TGN1412 wikiPageWikiLink National_Institute_for_Biological_Standards_and_Control.
- TGN1412 wikiPageWikiLink New_Scientist.
- TGN1412 wikiPageWikiLink No-observed-adverse-effect_level.
- TGN1412 wikiPageWikiLink Northwick_Park_Hospital.
- TGN1412 wikiPageWikiLink Opsonin.
- TGN1412 wikiPageWikiLink Orphan_drug.
- TGN1412 wikiPageWikiLink PAREXEL.
- TGN1412 wikiPageWikiLink Paul_Ehrlich_Institute.
- TGN1412 wikiPageWikiLink Phagocytosis.
- TGN1412 wikiPageWikiLink Pharmacovigilance.
- TGN1412 wikiPageWikiLink Placebo.
- TGN1412 wikiPageWikiLink Placebo-controlled_study.
- TGN1412 wikiPageWikiLink Plasmapheresis.
- TGN1412 wikiPageWikiLink Pre-clinical_development.
- TGN1412 wikiPageWikiLink Primate.
- TGN1412 wikiPageWikiLink Protocol_(science).
- TGN1412 wikiPageWikiLink Regulatory_T_cell.
- TGN1412 wikiPageWikiLink Rheumatoid_arthritis.
- TGN1412 wikiPageWikiLink Secretary_of_State_for_Health.
- TGN1412 wikiPageWikiLink Skin.
- TGN1412 wikiPageWikiLink Statistics.
- TGN1412 wikiPageWikiLink T_cell.
- TGN1412 wikiPageWikiLink T_cell_receptor.
- TGN1412 wikiPageWikiLink TeGenero.
- TGN1412 wikiPageWikiLink The_Sunday_Times.
- TGN1412 wikiPageWikiLink University_of_Sheffield.
- TGN1412 wikiPageWikiLink File:CD28_structure.gif.
- TGN1412 wikiPageWikiLink File:T_cell_activation.svg.
- TGN1412 wikiPageWikiLinkText "TGN1412".
- TGN1412 atcPrefix "none".
- TGN1412 legalStatus "never marketed".
- TGN1412 mabType "mab".
- TGN1412 molecularWeight "~148 g/mol".